Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Skyhawk Therapeutics Inc. currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 6 distinct examiners and 6 distinct art units, showing a high degree of variety in the prosecution of their current portfolio. Only one examiner is handling more than a single pending matter, while the rest of the workload is spread across different individuals and art units.
The busiest examiner for the company is LEE, CHIHYI NMN, who is responsible for 2 pending office actions. The remaining pending office actions are each assigned to one of the other distinct examiners. This distribution across 6 distinct art units for the 7 total actions suggests that the company's pending applications are being reviewed by several different specialized groups within the USPTO, with minimal overlap between them.
For practitioners, this means that prosecution strategies must be tailored to 6 different examiners and the various art units. While LEE, CHIHYI NMN is the busiest with 2 pending actions, the overall portfolio is not concentrated under any single person or unit. The 7 pending office actions require navigating the specific preferences and historical trends of 6 distinct art units, making a unified prosecution approach difficult to implement across the entire pending set.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 5 (83%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 2 | 33.3% | +61.1% |
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19177271 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | DIAMOND, ALAN D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864033 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | CHANDRAKUMAR, NIZAL S | — |
| 18864030 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | NESTOR, DONNA MICHELLE | — |
| 18858878 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | MOORE, SUSANNA | — |
| 18707167 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | LEE, CHIHYI NMN | — |
| 18707168 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 3991 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19177271 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | DIAMOND, ALAN D | 3991 | §102§103§112 | Final Rejection | — | Pending | Apr 11, 2025 |
| 18864033 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | CHANDRAKUMAR, NIZAL S | 1625 | §112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18864030 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | NESTOR, DONNA MICHELLE | 1627 | §102§112DP | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18858878 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | MOORE, SUSANNA | 1624 | §112DP | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18707167 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | May 03, 2024 |
| 18707168 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | May 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSkyhawk Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Chihyi Nmn Lee has the most, with 2 of Skyhawk Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
